FibroGen Inc
FibroGen Inc logo
FGEN

FibroGen Inc (FGEN)

$16.489.57%

Market is closed
– opens on 8 PM, 05 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$14.098
Day's Range
$16.55
$7.81
52-Week Range
$18.31
1 month return1.42%
3 month return34.42%
1 year return16.14%
5 year return62.97%

Company Information

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF).
OrganizationFibroGen Inc
Employees566
CEOMr. Enrique A. Conterno
IndustryHealth Technology

Analyst Recommendation

based on 9 analysts ratings

Hold
11%
Buy
77%
Hold
11%
Sell

Based on 9 Wall street analysts offering stock ratings for FibroGen Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Downside of 0.49%

Current

$16.48

Target

$16.4

Recommendation Trend

Based on 9 analyst

Current1M Ago3M Ago
Buy
1
0
0
Hold
7
8
8
Sell
1
4
4
Consensus
HOLD
HOLD
HOLD

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
1.4B
Book Value
$0.28
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.04
PEG Ratio
0.0
Wall Street Target Price
16.4

Valuation

Trailing PE0.0
Forward PE61.35
Price/Book (mrq)
50.9
Enterprise Value
1.0B
Enterprise Value/Revenue
8.32
Enterprise Value/Ebitda
-2.9

Technicals

Beta
0.87
50 Day MA
14.97
200 Day MA
12.65

Institutional Holdings

PRIMECAP Management Company

14.03%

Vanguard Group Inc

10.37%

Point72 Asset Management, L.P.

5.39%

Armistice Capital, LLC

4.74%

State Street Corporation

4.5%

First Trust Advisors L.P.

3.86%

Discover more

Frequently Asked Questions

What is FibroGen Inc share price today?

Can Indians buy FibroGen Inc shares?

How can I buy FibroGen Inc shares from India?

Can Fractional shares of FibroGen Inc be purchased?

What are the documents required to start investing in FibroGen Inc stocks?

What are today’s High and Low prices of FibroGen Inc?

What are today’s traded volumes of FibroGen Inc?

What is today’s market capitalisation of FibroGen Inc?

What is the 52 Week High and Low Range of FibroGen Inc?

How much percentage FibroGen Inc is down from its 52 Week High?

How much percentage FibroGen Inc is up from its 52 Week low?

What are the historical returns of FibroGen Inc?

Who is the Chief Executive Officer (CEO) of FibroGen Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*